CCR5 antagonists are a powerful new class of antiretroviral drugs that require a companion assay to evaluate the presence of CXCR4-tropic (non-R5) viruses prior to use in human immunodeficiency virus (HIV)-infected individuals. In this study, we have developed, characterized, verified, and prevalidated a novel phenotypic test to determine HIV-1 coreceptor tropism (VERITROP) based on a sensitive cell-to-cell fusion assay. A proprietary vector was constructed containing a near-full-length HIV-1 genome with the yeast uracil biosynthesis (URA3) gene replacing the HIV-1 env coding sequence. Patient-derived HIV-1 PCR products were introduced by homologous recombination using an innovative yeast-based cloning strategy. The env-expressing vectors were then used in a cell-to-cell fusion assay to determine the presence of R5 and/or non-R5 HIV-1 variants within the viral population. Results were compared with (i) the original version of Trofile (Monogram Biosciences, San Francisco, CA), (ii) population sequencing, and (iii) 454 pyrosequencing, with the genotypic data analyzed using several bioinformatics tools, i.e., the 11/24/25 rule, Geno2Pheno (2% to 5.75%, 3.5%, or 10% false-positive rate [FPR]), and webPSSM. VERITROP consistently detected minority non-R5 variants from clinical specimens, with an analytical sensitivity of 0.3%, with viral loads of ≥1,000 copies/ml, and from B and non-B subtypes. In a pilot study, a 73.7% (56/76) concordance was observed with the original Trofile assay, with 19 of the 20 discordant results corresponding to non-R5 variants detected using VERITROP and not by the original Trofile assay. The degree of concordance of VERITROP and Trofile with population and deep sequencing results depended on the algorithm used to determine HIV-1 coreceptor tropism. Overall, VERITROP showed better concordance with deep sequencing/Geno2Pheno at a 0.3% detection threshold (67%), whereas Trofile matched better with population sequencing (79%). However, 454 sequencing using Geno2Pheno at a 10% FPR and 0.3% threshold and VERITROP more accurately predicted the success of a maraviroc-based regimen. In conclusion, VERITROP may promote the development of new HIV coreceptor antagonists and aid in the treatment and management of HIV-infected individuals prior to and/or during treatment with this class of drugs.

Institute of Organic Chemistry and Biochemistry Prague Czech Republic

Zobrazit více v PubMed

Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. 1984. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312:763–767 PubMed

Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, Gluckman JC, Montagnier L. 1984. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 312:767–768 PubMed

Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA. 1996. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC- CKR-5. Nature 381:667–673 PubMed

Feng Y, Broder CC, Kennedy PE, Berger EA. 1996. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872–877 PubMed

Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661–666 PubMed

Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, Moore JP, Sattentau QJ, Schuitemaker H, Sodroski J, Weiss RA. 1998. A new classification for HIV-1. Nature 391:240. PubMed

Frange P, Chaix ML, Raymond S, Galimand J, Deveau C, Meyer L, Goujard C, Rouzioux C, Izopet J. 2010. Low frequency of CXCR4-using viruses in patients at the time of primary non-subtype-B HIV-1 infection. J. Clin. Microbiol. 48:3487–3491 PubMed PMC

Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD. 1993. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261:1179–1181 PubMed

Bomsel M, David V. 2002. Mucosal gatekeepers: selecting HIV viruses for early infection. Nat. Med. 8:114–116 PubMed

Moyle GJ, Wildfire A, Mandalia S, Mayer H, Goodrich J, Whitcomb J, Gazzard BG. 2005. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J. Infect. Dis. 191:866–872 PubMed

Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. 1997. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185:621–628 PubMed PMC

Poveda E, Briz V, Quinones-Mateu M, Soriano V. 2006. HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS 20:1359–1367 PubMed

Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood A, Perros M. 2005. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49:4721–4732 PubMed PMC

Rose JD, Rhea AM, Weber J, Quinones-Mateu ME. 2009. Current tests to evaluate HIV-1 coreceptor tropism. Curr. Opin. HIV AIDS 4:136–142 PubMed

Weber J, Piontkivska H, Quinones-Mateu ME. 2006. HIV type 1 tropism and inhibitors of viral entry: clinical implications. AIDS Rev. 8:60–77 PubMed

Trouplin V, Salvatori F, Cappello F, Obry V, Brelot A, Heveker N, Alizon M, Scarlatti G, Clavel F, Mammano F. 2001. Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J. Virol. 75:251–259 PubMed PMC

Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, Wrin T, Chappey C, Kiss LD, Paxinos EE, Petropoulos CJ. 2007. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob. Agents Chemother. 51:566–575 PubMed PMC

Raymond S, Delobel P, Mavigner M, Cazabat M, Souyris C, Encinas S, Bruel P, Sandres-Saune K, Marchou B, Massip P, Izopet J. 2010. Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. J. Clin. Virol. 47:126–130 PubMed

Holland AU, Munk C, Lucero GR, Nguyen LD, Landau NR. 2004. Alpha-complementation assay for HIV envelope glycoprotein-mediated fusion. Virology 319:343–352 PubMed

Grund S, Klein A, Adams O. 2010. Expression plasmids are only useful for the investigation of co-receptor tropism and fusion capacity of short HIV-1 envelope domains. J. Virol. Methods 166:106–109 PubMed

Obermeier M, Symons J, Wensing AM. 2012. HIV population genotypic tropism testing and its clinical significance. Curr. Opin. HIV AIDS 7:470–477 PubMed

Swenson LC, Moores A, Low AJ, Thielen A, Dong W, Woods C, Jensen MA, Wynhoven B, Chan D, Glascock C, Harrigan PR. 2010. Improved detection of CXCR4-using HIV by V3 genotyping: application of population-based and “deep” sequencing to plasma RNA and proviral DNA. J. Acquir. Immune Defic. Syndr. 54:506–510 PubMed

Swenson LC, Daumer M, Paredes R. 2012. Next-generation sequencing to assess HIV tropism. Curr. Opin. HIV AIDS 7:478–485 PubMed

Archer J, Braverman MS, Taillon BE, Desany B, James I, Harrigan PR, Lewis M, Robertson DL. 2009. Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. AIDS 23:1209–1218 PubMed PMC

Sing T, Low AJ, Beerenwinkel N, Sander O, Cheung PK, Domingues FS, Buch J, Daumer M, Kaiser R, Lengauer T, Harrigan PR. 2007. Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir. Ther. 12:1097–1106 PubMed

Jensen MA, Li FS, van ‘t Wout AB, Nickle DC, Shriner D, He HX, McLaughlin S, Shankarappa R, Margolick JB, Mullins JI. 2003. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J. Virol. 77:13376–13388 PubMed PMC

Cardozo T, Kimura T, Philpott S, Weiser B, Burger H, Zolla-Pazner S. 2007. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res. Hum. Retroviruses 23:415–426 PubMed

Rosen O, Sharon M, Quadt-Akabayov SR, Anglister J. 2006. Molecular switch for alternative conformations of the HIV-1 V3 region: implications for phenotype conversion. Proc. Natl. Acad. Sci. U. S. A. 103:13950–13955 PubMed PMC

Lin NH, Kuritzkes DR. 2009. Tropism testing in the clinical management of HIV-1 infection. Curr. Opin. HIV AIDS 4:481–487 PubMed PMC

Bjorndal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A, Albert J, Scarlatti G, Littman DR, Fenyo EM. 1997. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71:7478–7487 PubMed PMC

Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. (Lond.) 27:493–497

Poveda E, Seclen E, Gonzalez MM, Garcia F, Chueca N, Aguilera A, Rodriguez JJ, Gonzalez-Lahoz J, Soriano V. 2009. Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J. Antimicrob. Chemother. 63:1006–1010 PubMed

Moreno S, Clotet B, Sarria C, Ortega E, Leal M, Rodriguez-Arrondo F, Sanchez-de la Rosa R, Allegro Study Group 2009. Prevalence of CCR5-tropic HIV-1 among treatment-experienced individuals in Spain. HIV Clin. Trials 10:394–402 PubMed

Dudley DM, Gao Y, Nelson KN, Henry KR, Nankya I, Gibson RM, Arts EJ. 2009. A novel yeast-based recombination method to clone and propagate diverse HIV-1 isolates. Biotechniques 46:458–467 PubMed

Weber J, Vazquez AC, Winner D, Rose JD, Wylie D, Rhea AM, Henry K, Pappas J, Wright A, Mohamed N, Gibson R, Rodriguez B, Soriano V, King K, Arts EJ, Olivo PD, Quinones-Mateu ME. 2011. Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3′Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy. Antimicrob. Agents Chemother. 55:3729–3742 PubMed PMC

Archer J, Weber J, Henry K, Winner D, Gibson R, Lee L, Paxinos E, Arts EJ, Robertson DL, Mimms L, Quinones-Mateu ME. 2012. Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism. PLoS One 7:e49602 doi:10.1371/journal.pone.0049602 PubMed DOI PMC

Archer J, Baillie G, Watson SJ, Kellam P, Rambaut A, Robertson DL. 2012. Analysis of high-depth sequence data for studying viral diversity: a comparison of next generation sequencing platforms using Segminatr II. BMC Bioinformatics 13:47. PubMed PMC

Archer J, Rambaut A, Taillon BE, Harrigan PR, Lewis M, Robertson DL. 2010. The evolutionary analysis of emerging low frequency HIV-1 CXCR4 using variants through time—an ultra-deep approach. PLoS Comput. Biol. 6:e1001022 doi:10.1371/journal.pcbi.1001022 PubMed DOI PMC

Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, Jensen MA, Thielen A, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR. 2011. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J. Infect. Dis. 203:237–245 PubMed PMC

Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, Thielen A, Jensen MA, Knapp DJ, Chapman D, Portsmouth S, Lewis M, James I, Heera J, Valdez H, Harrigan PR. 2011. Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. Clin. Infect. Dis. 53:732–742 PubMed

Swenson LC, McGovern RA, Dong W, Mo T, Lee GQ, Thielen A, et al. 2009. Optimization of clinically relevant cutoffs for determining HIV co-receptor use by population and deep sequencing methods. Infectious Diseases Society of America 47th Annual Meeting Philadelphia, PA, 29 October to 1 November 2009

Reeves JD, Coakley E, Petropoulos CJ, Whitcomb JM. 2009. An enhanced-sensitivity Trofile™ HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies. J. Viral Entry 3:94–102

Paar C, Geit M, Stekel H, Berg J. 2011. Genotypic prediction of human immunodeficiency virus type 1 tropism by use of plasma and peripheral blood mononuclear cells in the routine clinical laboratory. J. Clin. Microbiol. 49:2697–2699 PubMed PMC

Moore JP, Kitchen SG, Pugach P, Zack JA. 2004. The CCR5 and CXCR4 coreceptors—central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses 20:111–126 PubMed

Soulie C, Calvez V, Marcelin AG. 2012. Coreceptor usage in different reservoirs. Curr. Opin. HIV AIDS 7:450–455 PubMed

Verhofstede C, Nijhuis M, Vandekerckhove L. 2012. Correlation of coreceptor usage and disease progression. Curr. Opin. HIV AIDS 7:432–439 PubMed

Raymond S, Delobel P, Izopet J. 2012. Phenotyping methods for determining HIV tropism and applications in clinical settings. Curr. Opin. HIV AIDS 7:463–469 PubMed

Japour AJ, Fiscus SA, Arduino JM, Mayers DL, Reichelderfer PS, Kuritzkes DR. 1994. Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J. Clin. Microbiol. 32:2291–2294 PubMed PMC

Princen K, Hatse S, Vermeire K, De Clercq E, Schols D. 2004. Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists. Retrovirology 1:2. PubMed PMC

Kajiwara K, Kodama E, Matsuoka M. 2006. A novel colorimetric assay for CXCR4 and CCR5 tropic human immunodeficiency viruses. Antiviral Chem. Chemother. 17:215–223 PubMed

Trkola A, Ketas T, Kewalramani VN, Endorf F, Binley JM, Katinger H, Robinson J, Littman DR, Moore JP. 1998. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J. Virol. 72:1876–1885 PubMed PMC

Meyerhans A, Cheynler R, Albert J, Seth M, Kwok S, Sninsky J, Morfeldt-Manson L, Asjî B, Wain-Hobson S. 1989. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell 58:901–910 PubMed

Gonzalez-Serna A, Leal M, Genebat M, Abad MA, Garcia-Perganeda A, Ferrando-Martinez S, Ruiz-Mateos E. 2010. TROCAI (tropism coreceptor assay information): a new phenotypic tropism test and its correlation with Trofile enhanced sensitivity and genotypic approaches. J. Clin. Microbiol. 48:4453–4458 PubMed PMC

Lineberger JE, Danzeisen R, Hazuda DJ, Simon AJ, Miller MD. 2002. Altering expression levels of human immunodeficiency virus type 1 gp120-gp41 affects efficiency but not kinetics of cell-cell fusion. J. Virol. 76:3522–3533 PubMed PMC

Nussbaum O, Broder CC, Berger EA. 1994. Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation. J. Virol. 68:5411–5422 PubMed PMC

Ji C, Zhang J, Cammack N, Sankuratri S. 2006. Development of a novel dual CCR5-dependent and CXCR4-dependent cell-cell fusion assay system with inducible gp160 expression. J. Biomol. Screen. 11:65–74 PubMed

Saliou A, Delobel P, Dubois M, Nicot F, Raymond S, Calvez V, Masquelier B, Izopet J. 2011. Concordance between two phenotypic assays and ultradeep pyrosequencing for determining HIV-1 tropism. Antimicrob. Agents Chemother. 55:2831–2836 PubMed PMC

Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H. 2008. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359:1429–1441 PubMed PMC

Su Z, Gulick RM, Krambrink A, Coakley E, Hughes MD, Han D, Flexner C, Wilkin TJ, Skolnik PR, Greaves WL, Kuritzkes DR, Reeves JD. 2009. Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. J. Infect. Dis. 200:1724–1728 PubMed PMC

Poveda E, Alcami J, Paredes R, Cordoba J, Gutierrez F, Llibre JM, Delgado R, Pulido F, Iribarren JA, Garcia Deltoro M, Hernandez Quero J, Moreno S, Garcia F. 2010. Genotypic determination of HIV tropism—clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. AIDS Rev. 12:135–148 PubMed

Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, James IT, Jenkins TM, Perros M, van der Ryst E. 2006. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J. Virol. 80:4909–4920 PubMed PMC

Marier JF, Trinh M, Pheng LH, Palleja SM, Martin DE. 2011. Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naive patients. Antimicrob. Agents Chemother. 55:2768–2774 PubMed PMC

Gonzalez N, Perez-Olmeda M, Mateos E, Cascajero A, Alvarez A, Spijkers S, Garcia-Perez J, Sanchez-Palomino S, Ruiz-Mateos E, Leal M, Alcami J. 2010. A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism. J. Antimicrob. Chemother. 65:2493–2501 PubMed

Skrabal K, Low AJ, Dong W, Sing T, Cheung PK, Mammano F, Harrigan PR. 2007. Determining human immunodeficiency virus coreceptor use in a clinical setting: degree of correlation between two phenotypic assays and a bioinformatic model. J. Clin. Microbiol. 45:279–284 PubMed PMC

de Mendoza C, Van Baelen K, Poveda E, Rondelez E, Zahonero N, Stuyver L, Garrido C, Villacian J, Soriano V. 2008. Performance of a population-based HIV-1 tropism phenotypic assay and correlation with V3 genotypic prediction tools in recent HIV-1 seroconverters. J. Acquir. Immune. Defic. Syndr. 48:241–244 PubMed

Raymond S, Delobel P, Mavigner M, Cazabat M, Souyris C, Sandres-Saune K, Cuzin L, Marchou B, Massip P, Izopet J. 2008. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 22:F11–F16 PubMed

Trabaud MA, Icard V, Scholtes C, Perpoint T, Koffi J, Cotte L, Makhloufi D, Tardy JC, Andre P. 2012. Discordance in HIV-1 co-receptor use prediction by different genotypic algorithms and phenotype assay: intermediate profile in relation to concordant predictions. J. Med. Virol. 84:402–413 PubMed

Recordon-Pinson P, Soulie C, Flandre P, Descamps D, Lazrek M, Charpentier C, Montes B, Trabaud MA, Cottalorda J, Schneider V, Morand-Joubert L, Tamalet C, Desbois D, Mace M, Ferre V, Vabret A, Ruffault A, Pallier C, Raymond S, Izopet J, Reynes J, Marcelin AG, Masquelier B. 2010. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob. Agents Chemother. 54:3335–3340 PubMed PMC

Seclen E, Soriano V, Gonzalez MM, Gomez S, Thielen A, Poveda E. 2011. High concordance between the position-specific scoring matrix and geno2pheno algorithms for genotypic interpretation of HIV-1 tropism: V3 length as the major cause of disagreement. J. Clin. Microbiol. 49:3380–3382 PubMed PMC

Contribution of human immunodeficiency virus type 1 minority variants to reduced drug susceptibility in patients on an integrase strand transfer inhibitor-based therapy